Litcius/Paper detail

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, George Follows, André Goy, Joost S.P. Vermaat, Olivier Casasnovas, Nada Hamad, Josée M. Zijlstra, Sameer Bakhshi, Réda Bouabdallah, Sylvain Choquet, Ronit Gurion, Brian T. Hill, Ulrich Jaeger, Juan‐Manuel Sancho, Michael Schuster, Catherine Thiéblemont, Fátima De la Cruz, Miklós Egyed, Sourav Mishra, Fritz Offner, Theodoros P. Vassilakopoulos, Krzysztof Warzocha, Daniel McCarthy, Xiwen Ma, Kelly Corona, Jean-Richard Saint-Martin, Hua Chang, Yosef Landesman, Anita Joshi, Hongwei Wang, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Éric Van Den Neste, Miguel Canales

2020The Lancet Haematology337 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineRefractory (planetary science)Diffuse large B-cell lymphomaPhases of clinical researchLymphomaClinical trialTransplantationOncologyGastroenterologySurgeryAstrobiologyPhysicsNuclear Structure and FunctionCell death mechanisms and regulationHeat shock proteins research